Program - Society of Toxicology

44 th Annual Meeting
and ToxExpo
Program Description
#327 1:30 ENVIRONMENTAL TERRORISM:
DEVELOPMENT OF EVACUATION, RE-ENTRY
AND RE-USE GUIDELINES FOR CHEMICAL,
BIOLOGICAL AND RADIOLOGICAL AGENTS.
M. A. Maddaloni. U.S. EPA, New York. Sponsor: A.
Jarabek.
#328 1:45 AN EPA PERSPECTIVE ON CHEMICAL
CONTAMINATION CLEAN-UP. S. Sterling, I. P.
Baumel and C. Sonich-Mullin. ORD/NHSRC, U.S.
EPA, Washington, DC. Sponsor: M. Maddaloni.
#329 2:15 A MILITARY APPROACH TO ASSESSING
HEALTH RISK. V. Hauschild and B. Thran.
Directorate of Health Risk Management, US Army Ctr
for Health Promotion and Preventive Medicine,
Aberdeen Proving Ground, Edgewood Area, MD.
Sponsor: M. Maddaloni.
#330 2:45 BIOTERRORIST THREATS TO THE US FOOD
SUPPLY SYSTEM: A RISK ASSESSMENT
PERSPECTIVE. B. Hope. Air Quality Division,
Oregon Department of Environmental Quality, Portland,
OR. Sponsor: A. Jarabeck.
#331 3:15 A PRIMER ON RADIATION ISSUES RELATED
TO NUCLEAR TERRORISM. S. L. Simon.
Radiation Epidemiology Branch, National Cancer
Institutes, Bethesda, MD. Sponsor: M. Maddaloni.
#332 3:45 DEVELOPMENT OF OPERATIONAL
GUIDELINES FOR CONSEQUENCE
MANAGEMENT OF RADIOLOGICAL
DISPERSAL DEVICE INCIDENTS. S. Domotor 1 , A.
Wallo 1 , C. YU 2 , D. LePoire 2 and S. Kamboj 2 . 1 US
DOE, Washington, DC and 2 Argonne National
Laboratory, Washington, DC. Sponsor: A. Jarabek.
Monday Afternoon, March 7
1:30 PM to 4:30 PM
Room RO6
WORKSHOP SESSION: HIGH THROUGHPUT SCREENING
APPROACHES IN GENETIC TOXICOLOGY
Chairperson(s): Jiri Aubrecht, Pfizer, Inc., Groton, CT and Robert Schiestl,
University of California, Los Angeles, Los Angeles, CA.
Endorsed by:
In Vitro SS*
Risk Assessment SS
Recent progress in combinatorial chemistry, molecular biology, genomics, and
automation has enabled identifying a relatively large number of compounds
capable of reacting with intended pharmacological targets. However, 40% of
drug candidates ultimately fail during clinical development due to safety related
issues. The overall attrition of drug candidates due to genetic toxicology issues
alone includes about 12% of drug candidates. This causes delays in the introduction
of vital drugs to patients and significant economic losses. Therefore, the
development of relevant mechanism-based high throughput screening technologies
to assess genetic toxicity at the early stages of drug discovery with
relatively limited amount of chemical is extremely important. Genetic toxicology
provides the necessary information for assessment of the genotoxic risk
associated with the use of drugs. Since the beginning of genotoxicity testing in
the early 1970s, many different test systems have been developed and used.
Since no single test is capable of detecting all genotoxic agents, the current standard
in vitro genotoxicity testing consists of evaluating mutagenicity (bacterial
reverse mutation assay) and chromosome damage (lymphocyte aberration assay
or mouse lymphoma assay). Unfortunately, these standard in vitro assays are not
amenable to high throughput testing and their application in early phases of drug
discovery is not feasible. Therefore, the research and assay development efforts
have been directed to developing alternative approaches, technologies and/or
endpoints. The speakers in this session present emerging state-of-the-art technologies
under development and/or currently used in the pharmaceutical
industry. The topics covered in this symposium comprise high throughput
versions of the Salmonella assay, assays for DNA deletions, chromosome aberrations,
the comet assay and a gene expression reporter assay. The presentations
will cover exciting developments that may spark further interest in the automation
of genotoxicity assays.
#333 1:30 HIGH THROUGHPUT SCREENING
APPROACHES IN GENETIC TOXICOLOGY. R.
H. Schiestl 2 and J. Aubrecht 1 . 1 Safety Sciences, Pfizer,
Inc., Groton, CT and 2 Departments of Pathology and
Environmental Health, UCLA, Los Angeles, CA.
#334 1:40 BIOLUMINESCENT SALMONELLA REVERSE
MUTATION ASSAY: A HIGH THROUGHPUT
APPROACH FOR DETECTION OF
MUTAGENICITY. J. Aubrecht. Safety Sciences,
Pfizer, Inc., Groton, CT.
#335 2:10 BIOLUMINESCENT YEAST DEL ASSAY TO
DETECT CARCINOGENS AND CLASTOGENS. R.
Schiestl 1 and J. Aubrecht 2 . 1 Pathology, UCLA, Los
Angeles, CA and 2 Safety Sciences, Pfizer, Inc., Groton,
CT.
#336 2:40 APPLICATION OF A HIGH THROUGHPUT
COMET ASSAY IN DRUG DISCOVERY. A.
Hartmann 1 and W. Frieauff 2 . 1 Non Clinical Safety,
F.Hoffmann-La Roche Ltd., Basel, Switzerland and
2 GenSafe / Precinical Safety, Novartis Pharmacology,
Basel, Switzerland. Sponsor: J. Aubrecht.
MONDAY
up-to-date information at www.toxicology.org 73